. Author manuscript; available in PMC: 2013 Mar 7.

Published in final edited form as: Clin Infect Dis. 2010 Apr 15;50(8):1192–1197. doi: 10.1086/651419

Table 2.

Risk of Replication of Human Immunodeficiency Virus (HIV) of >400 Copies/mL by Average Percent and Patterns of Adherence

Variable	HIV control^a (n = 56)	HIV replication (n = 16)	OR^b (95% CI)	P
Adherence rate,^c mean ± SD, %	89.2 (11.6)	36.8 (19.4)	0.27 (0.14–0.53)	<.001
No. of days without dose,^d mean ± SD	8 (10)	38 (27)	1.08 (1.04–1.12)	<.001
No. of TIs,^e mean ± SD	3.2 (5.1)	11.7 (5.8)	1.24 (1.09–1.39)	.001
Duration of longer TIs, mean ± SD, days	4.9 (5.6)	20.0 (14.9)	1.22 (1.10–1.36)	.002

NOTE. CI, confidence interval; OR, odds ratio; SD, standard deviation; TIs, treatment interruptions.

HIV RNA level of <400 copies/mL at the end of adherence monitoring; results were similar with an HIV RNA level of <50 copies/mL.

Computed by use of logistic regression. An OR of >1 means an increased probability of HIV replication.

OR and 95% CI are provided for a 10% increase in adherence rate.

Defined as discontinuation of drugs for >24 h and <48 h.

Defined as discontinuation of drugs for >48 h.